John P. Iwanicki presents “Demystifying the Current Obviousness Standard and Its Implications for Biotech Patenting” at ACI’s 14th Advanced Forum on Biotech Patents in Boston
Mr. Iwanicki co-presents with Eli Lilly & Company’s Assistant General Patent Counsel, Alexander Wilson on Thursday, November 29 at 4:30 p.m. at the Hyatt Regency Boston, in Boston, MA.
Elements of the presentation will include:
- Exploring the reaffirmation of KSR though In re Kao
- Understanding the impact of KSR and its progeny on primary compound and compositions claims
- Assessing the implications of Otsuka Pharm. v. Sandoz
- Describing how Otsuka clarifies the obvious-type double patenting analysis
- Determining the interplay between obvious-type double patenting analysis and traditional obviousness analysis elucidated in Otsuka
- Characterizing the role of “lead compound” designation in obviousness findings
- Utilizing obvious-type double patenting claims as a litigation tool
- What is “structural” obviousness?
- Grasping the growing importance of unexpected results
- Recognizing the tension created when emphasizing unexpected results runs up against written description requirements
- Investigating the CAFC’s trend towards granting credence towards “secondary considerations” in obviousness analysis
- Considering the PTO’s recent embracing of secondary considerations when examining patent applications
- Why does the CAFC weigh secondary considerations equally with unexpected results in obviousness analysis?
For more information including registration information, please visit www.americanconference.com/biotechpatents.